Research & Development
Professional, Innovation, and Respect of life
We are a global, new drug developing biopharmaceutical company provide only evidence-based medicine.
Established in 2008, SynCore was cofounded by Sinphar Group and National Health Research Institute (NHRI) Taiwan. We focus on creating values of new drug by R&D management and integration of technology resources. SynCore’s pipeline concentrates on oncology, ophthalmology, and dermatology fields, continuously dedicates in helping patients worldwide.
SynCore Biotechnology Announces Interim Analysis Results for Novel Pancreatic Cancer Asset, SB05PC (EndoTAG®-1)
SynCore Biotechnology (4192:TT) receives interim analysis results for its global phase [...]
SB05 Pancreatic Cancer Clinical Trial Reaches Conditions to Conduct Interim Analysis
SynCore’s global phase III clinical trial on pancreatic cancer second-line therapy, [...]
Syncore Biotechnology to Participate at the Biotech Showcase 2022 Conference
Syncore Biotechnology will attend the Biotech Showcase 2022 Conference virtually on [...]
SynCore Biotechnology to attend the 2022 BIO Partnering at JPM
SynCore Biotechnology (SynCore Bio) is pleased to announce that it will [...]